Global Osteoporosis Drugs Market is Anticipated to Register at a Healthy CAGR of 4.0% by 2022


The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.
However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits the growth of the market.

The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn by the end of 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period.



In North America, the prevalence of osteoporosis 
is high primarily due to increasing geriatric population, growing obesity, and rising prevalence of lifestyle associated diseases in the region. According to the National Osteoporosis Foundation, in 2013, approximately 54 million people in the U.S. aged 50 years and above were affected by osteoporosis and low bone mass. According to the U.S. Department of Health and Human Services, in the U.S., approximately 250,000 hip fractures are associated with osteoporosis. 


A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/2983


In Europe, increasing aging population, changing lifestyles, and increasing consumer awareness about osteoporosis care are driving the growth of the osteoporosis drug market. According to the International Osteoporosis Foundation, approximately 5.5 million men and 22 million women suffered from osteoporosis in 2010. Moreover, according to International Osteoporosis Foundation, approximately 27.5 million people in Europe suffered from osteoporosis in 2010 and the number is expected to reach 33.9 Mn by 2030.
However, the growth of osteoporosis market in Asia Pacific is much due to rising geriatric population and changing lifestyles in the region. 


Osteoporotic patients have a higher risk of hip fractures, owing to a major cause of morbidity and mortality. According to the International Osteoporosis Foundation, by 2050, approximately 50% of the world’s osteoporosis hip fractures would occur in women in Asia. In addition, according to a study on Epidemiology in Osteoporosis in Japan by the National Centre for Biotechnology Information, in 2011, approximately 15 million people suffered from osteoporosis in Japan.

Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Merck & Co. Inc., Novartis AG, Amgen, Inc., Actavis plc, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc. are some of the major players of osteoporosis drugs market.

Comments

Post a Comment

Popular posts from this blog

Head Guards Market is Expected to Witness a Steady Growth by 2028

Market Overview Safety equipment plays an important role in protecting sports enthusiasts from various injuries. Head guard is the key protection equipment widely used in games like boxing, baseball and rugby. This equipment has gained traction among athletes from amateur to professional players in both, national and international competitions. Rising number of national and international sports competitions globally, the demand for head guards has surged, which will in turn increase the volume of head guard sells from retail outlets to the company online sales channel. Many sports associations such as World Rugby, International Baseball Federation and World Boxing Association have necessitated the use of head guards for players in sports matches. In baseball alone, there are over 35 million players at different levels, and the U.S. houses close to 14 million amateur and professional players. This massive number of participants in baseball creates a significant customer base for h...
Read more

Die Cut Box Market to Witness an Outstanding Growth by 2028

Die Cut Box Marke t: Overview Die cut box is an innovative packaging solution for multiple end-use sectors. Growing need for fast moving consumer goods, ingenious packaging formats from design, and size perspective,  die cut box continues to offer an advantageous edge in product positioning. Die cut box allows the leading brands and manufacturers to integrate novel design elements, which in turn assures a higher threshold of customer acquisition viz.a.viz. effective branding and marketing. Besides industry specific drivers and trends, macroeconomic factors will also continue to influence demand for the die cut box across industries. Such factor include but aren’t limited to per capita disposable income, food retail sector growth, modern retail establishment growth etc. Outpacing growth in the e-commerce sector has gained traction for the corrugated packaging industry. Die cut box cost wouldn’t be a big burn to the pocket of die cut box manufacturers despite the re-usability of ...
Read more

Gynaecological Cancer Drugs Market Accounting US$ 41,855.8 million by 2026

The new report by Persistence Market Research (PMR) expects the global gynaecological cancer drugs market to witness significant growth, registering 6.2% CAGR during the forecast period. The global gynaecological cancer drugs market is also expected to bring in US$ 41,855.8 million revenue by the end of 2026. Treatment of cancer is being increasingly focused on be leading pharmaceutical companies, researchers, healthcare institutes and governments of various countries. With increasing number of research and development activities in cancer treatment, especially in gynaecological cancer treatment, new treatments are reaching an increasing number of physicians faster than ever. Also, availability of advanced treatment options and drugs has resulted in the decline in cancer mortality rate across major developed countries. However, the scenario is not same in the developing nations. This is due to the high cost of cancer treatment and lack of availability of new treatments. Gynaecologi...
Read more